



# **Cytokines' network in PsA/SpA**

George Fragoulis

Assistant Prof Rheumatology, Hospital "Laiko"


# Conflicts of interest

---

- ➔ Honoraria/Speaker fees
  - ❖ Abbvie, Aenorasis, Pfizer, Novartis, UCB, Janssen, Lilly, Amgen

# Spondyloarthritis

## Axial spondyloarthritis (AxSpA) and Psoriatic arthritis (PsA)



# SpA

## Shared Clinical manifestations

- ◆ PsA and AxSpA

- Share clinical manifestations
- Inflammatory bowel disease (AxSpA [15-30%] > PsA [5%])
- Uveitis (AxSpA [10-20%] > PsA [5%])
- Psoriasis (PsA>AxSpA [10%])
- Peripheral arthritis (PsA>AxSpA)
- Axial Disease (AxSpA [100%] > PsA [25%])



SpA

# Pathogenesis


---

- ➔ Genetic factors
- ➔ Environmental factors
  - ◆ Microbiome
- ➔ Mechanical stress

# Pathogenesis Genetics HLA

## → HLA-B27

- ◆ In AxSpA
- ◆ In about 20-30% of PsA
- ◆ Associated with
  - ✿ Axial disease
  - ✿ Dactylitis
  - ✿ Uveitis
  - ✿ Poor prognosis



# SpA pathogenesis

## Genetics....and non-HLA

### ► Genetic factors

- ◆ Outside HLA – mainly in pathways
  - ✿ IFN
  - ✿ TNF
  - ✿ IL-23/-17

Gene	PSO	PsA
<b>HLA</b>		
PSORS1	X	X
HLA-C*0704	X	
HLA-C*1203	X	
HLA-B27	X	X
HLA-B57	X	X
HLADQA1	X	
HLA-B13		X
HLA-B08		X
HLA-B37	X	
HLA-B38		X
HLA-B39		X
HLA-DRB1*04		X
IFN signalling		
ELMO1	X	
SOCS1	X	
RNF114	X	
IFIH1	X	
MDA5	X	
DDX58	X	
TYK2	X	X
IL-23/17 signalling		
IL-23A (p19)	X	X
IL-12B (p40)	X	X
IL-23R	X	X
TYK2	X	X
JAK2	X	
STAT3	X	X
TRAF3IP2	X	X
SOCS1	X	
ETS1	X	


# SpA pathogenesis

## Environmental factors

- ➔ Environmental factors
  - ◆ Microbiome
- ➔ HLA-B27 Tg mice or SKG mice
  - ◆ IBD-like, psoriasis-like rash, arthritis, sacroiliitis
    - ✿ Less pronounced in germ free conditions
- ➔ Psoriatic arthritis Vs Healthy individuals
  - ◆ ↓ Akkermansia/Ruminococcus/Coprococcus


# Cytokines

Different drivers according to disease type? (Updated?)



# The cytokines


## IL-23/IL-17/TNF/IL-22



# IL-17

## the players

- 6 members (IL-17A through -F)
  - IL-17A and IL-17F the most well characterized
  - Form homodimers and heterodimers
    - which act with diverse affinity
    - through the five IL-17 receptors (IL-17Rs)



# IL-17

## PsA

- Mononuclear cells

- Synovial fluid (SF)
- PsA (n = 20), RA (n = 20), OA (n = 20)
  - \* ↑ Th17 in PsA (SF)

**Table 1** Enrichment of CD4+ IL-17+ T lymphocytes in the synovial fluid of psoriatic arthritis patients compared to the controls

Study group	%CD4+IL-17+ T lymphocytes (mean ± SD)	
	SFMC	PBMC
Psoriatic arthritis (n = 12)	7.9 ± 2.8*	0.9 ± 0.6
Rheumatoid arthritis (n = 8)	8.2 ± 3.1*	1.0 ± 0.6
Osteoarthritis (n = 12)	0.7 ± 0.3	0.6 ± 0.2
Healthy volunteers (n = 12)	Not done	0.6 ± 0.2

\* P < .001, Student *t* test, comparison between psoriatic arthritis and osteoarthritis; and rheumatoid arthritis and osteoarthritis. SFMC synovial fluid mononuclear cells, PBMC peripheral blood mononuclear cells

# IL-17

## PsA

### ↳ Synoviocytes (FLS)

- ◆ PsA (n = 5), RA (n = 5), OA (n = 5)



- ◆ IL-17R

- Higher in PsA

- rIL-17 induced

- ✓ IL-6, IL-8, and MMP-3 production in PsA-FLS

- anti-IL-17RA antibody inhibited the production of IL-6, IL-8, and MMP-3



# IL-17

## AxSpA

### PBMCs





◆ AS (n=20) Vs RA (n=12) Vs HC (n=16)

◆ ↑ AS Vs HC

● PBMCs: % of IL-17-CD4+ T cells

● PBMCs: % IL-22-CD4+ T cells


● IL-17



# IL-17

## SpA – meta-analysis

- 138 studies
- ↑ AS vs HC
  - ◆ % Th17 cells
    - ✿ ↑ in active AS




# IL-17

## SpA – meta-analysis

### ◆ Levels of IL-17


#### ◆ ↑ AS vs HC



**Fig. 6** Forest plot of IL-17A. The level of peripheral IL-17A was higher in patients with AS (AS) than in healthy controls

# Pathogenesis

## The IL-23/IL-17 axis



McGonagle D et al Ann Rheum Dis 2019  
Sieper J et al Nat Rev Rheum 2019


Siebert S, Fragoulis GE, McInnes IB EULAR online course 2016

**Inflammatory cytokines, chemokines, RANKL, cell activation**

# IL-23

## Mode of action

- Engagement of IL-23 with the IL-23R
  - ❖ Signalling, mainly through JAK2 and TYK2
    - Phosphorylation of STAT3
    - Subsequent expression of the transcription factor ROR $\gamma$ t and production of IL-17



# IL-23

## Evidence for SpA

---


→ In

- ◆ Entheses
- ◆ Spine
- ◆ Bowel
- ◆ Joints
- ◆ Skin

# IL-23

## Enthesis


- Enthesis organ “synovio-enthesial concept”
- Could enthesis be the start of everything??
- T-cells at the sites of tendon insertion into bone (enthuses)
  - ♦ express IL-23 receptor
  - ♦ respond to systemically-administered IL-23 to produce IL-17, IL-22 and IL-6



# ECLIPSA

## Enthesitis



- ❖ Prospective randomized RCT
- ❖ Ustekinumab (n=23) >> TNFi (n=24)
- ❖ At week 24
- ❖ more ustekinumab- than TNF-treated patients
  - ◆ SPARCC Enthesitis Index = 0 (74% versus 42%, respectively; p = 0.018)
- ❖ similar results observed for MASES = 0, LEI = 0, and for all three scores = 0



# IL-23

## Axial entheses


- IL-23
  - ↑ IL-23 facet SpA



# IL-23

## Bowel



- ➔ IL-23 has been found to be overexpressed in the gut of AS patients
  - ◆ By infiltrating monocytes
  - ◆ Paneth cells



# IL-23

## Synovium Vs Skin



- ❖ Similarities & differences
  - ❖ IL-23/-17 axis
    - ❖ More active in the skin Vs synovium




# PsA Pathogenesis

## Could all start from IL-23?

- Transgenic expression of IL-23 in mice




p19/p40  
expression  
in the ears



H&E, ears  
6 weeks



# IL-23 mice model

## PsA features & cytokines expression





# IL-23

## Initiation but not perpetuation of disease



# IL-23 in early enthesitis


- 73 new pso patients (topical Tx)
  - ◆ 49% had US enthesitis
    - ✿ 23 consented to participate
      - ✓ Compared with healthy volunteers
      - ✓ Entheseal abnormalities (thickening, PD): 24.2% Vs 4.5 %
      - ✓ Damage: 15.9% vs 6%
    - ✿ Treatment with Ustekinumab
      - ✓ Improved Enthesitis
      - ✓ But not damage



# IL-23 inhibitors


## Disease interception ?

- USA electronic health records
  - ◆ 15,501 PsO patients
    - ✿ 6.3% developed PsA
    - ✿ cumulative incidence of 2.6 cases per 100 person-years
- Treatment with IL-23i Vs TNFi or IL-17
  - ◆ According to first biologic class prescribed
  - ◆ associated with ↓ risk of progression to PsA inflammatory arthritis
    - ✿ The results persisted in all 6 sensitivity analyses (e.g other definitions, drug switching etc)



# PsA Pathogenesis

## The IL-23/IL-17 axis



McGonagle D et al Ann Rheum Dis 2019  
Sieper J et al Nat Rev Rheum 2019


Siebert S, Fragoulis GE, McInnes IB EULAR online course 2016

Inflammatory cytokines, chemokines, RANKL, cell activation

# PsA pathogenesis

## Rare subpopulations

- MAIT
- ILC
- Tgd



# MAIT

## Healthy


- ◆ Present in

- ✿ Axial entheses

- ✓ Able to produce TNF and IL-17
    - ✓ AHR, JAK1, STAT4, and TGF $\beta$ 1, CCR6, CCR3 expression

- ✿ Blood




- ✓ Able to produce IL-17
    - ✓ Transcripts expressed in T circulating lymphocytes



# MAIT

## In PsA – not many data


- ▶ PBMCs and SF
- ▶ PsA, RA, HC, n=10 each
  - ◆ MAIT cells were enriched in **synovial fluid** of PsA
- ▶ Upon stimulation SFMC MAIT cells
  - ◆ produced ↑ IL-17A in PsA Vs RA, OA
  - ◆ upregulation of IL-23R
    - \* IL-23R was functionally active



# MAIT

## AS - blood

- 30 AS Vs 21 HC
- % MAIT was reduced
  - ↑ MAIT producing IL-17
  - ↑ activated (CD69) MAIT
    - Associated with disease activity






# MAIT

## AS - blood

- Peripheral blood 36 AS Vs 55 HC

- MAIT





- ↓ Vs HC
    - ↑ IFN- $\gamma$ +/IL-17A+ MAIT cells
    - ↑ IL-22+ MAIT



# MAIT

## AxSpA - blood




- 18 AxSpA pts
  - MAIT produce
    - IL-17
    - IL-23R
    - IFNg



# MAIT

## AxSpA - blood

- ➔ AxSpA, RA, HC
  - ❖ Peripheral blood
  - ❖ In AxSpA
    - ✿ MAIT were less
    - ✿ But produced more IL-17
      - ✓ Especially in males
    - ✿ Homing molecules (CCR6)
      - ✓ ↑ peripheral blood



# CCR6 - migration

---


- ➔ CCR6
  - ◆ Involved in cells migration
  - ◆ present on B and T cells as well as dendritic cells (DCs).
  - ◆ Bind to CCL20
    - ✿ only known ligand
  - ◆ Both CCR6 and CCL20 are expressed by Th17 cells

# MAIT

## AxSpA - synovial fluid

### → AxSpA

- ◆ Even more in SF
- ✿ Phenotype towards
  - ✓ IL-17
  - ✓ Granzyme B+
- ✿ Activated (CD69)
  - ✓ IL-7 but not IL-23 dependent



# IL-7

## SpA - Synovial fluid

- SpA (n=10), RA (n=8), OA (n=5)
- IL-7 in the synovial fluid of SpA patients




Figure 2. Expression of candidate molecules, as assessed at the mRNA level by quantitative reverse transcriptase-polymerase chain reaction study of synovial fluid (SF) cells (A and B) or synovial tissue (ST) (C), and at the protein level by enzyme-linked immunosorbent assay of SF (D-F). Synovial samples were obtained from patients with spondyloarthritis (SpA), rheumatoid arthritis (RA), and osteoarthritis (OA). Values are the mean and SEM. IL-7 = interleukin-7; TNF = tumor necrosis factor.

# IL-7

## PsA - Synovial fluid



### → Synovial fluid

- ◆ 13 PsA vs 4 OA

- \* 39 proteins were found ↑ in SF PsA Vs OA patients

✓ Among these



- ~ TNF
- ~ IL-17A,
- ~ IL-6
- ~ IL-10
- ~ IFNg
- ~ IL-7



# MAIT

## AxSpA - blood (IL-17)

- IL-17 MAIT in AxSpA
  - Driven by IL-7 and IL-18




# MAIT

## AxSpA - IL-7


### PBMCs

- ◆ Express IL-7R (AxSpA>HC)
- ◆ Produce, upon priming with IL-7
  - ✿ Granzyme B
  - ✿ TNF $\alpha$
  - ✿ IL-17
- ✓ Different Vs HC



# IL-7

- ❖ IL-7/IL-7R signaling
  - ❖ IL-7 is mainly produced by
    - ✿ stromal cells
    - ✿ epithelial cells
    - ✿ Keratinocytes
    - ✿ dendritic cells
  - ❖ consumed by IL-7R expressing cells for
    - ✿ Development
    - ✿ Proliferation
    - ✿ Survival
    - ✿ maintenance



# Summary


---

- ➔ MAIT
  - ◆ Present and active in axial entheses
  - ◆ Main producers **of IL-17** (blood)
    - \* Under IL-7
  - ◆ Migrate to joints? (CCR6)
  - ◆ More data needed for PsA


# PsA pathogenesis

## Rare subpopulations

- MAIT
- ILC
- Tgd



## A Classification of ILCs




# ILC3

- Related to lymphoid tissue induced cells (LTi)

- Induced by IL-7

- LTi (lymphoid tissue inducer cells)



- Appear in lymphoid organs
    - Fetal>adults (intestine)
  - Produce lymphotxin ( $LT\alpha_1\beta_1$ ) and tumor necrosis factor (TNF)
    - Stimulating the mesenchymal cell production of chemokines and adhesion molecules essential for lymphoid organogenesis
    - Some of them express receptors found in NK cells
  - Express ROR $\gamma$ t & IL-23R
  - Produce IL-22, IFN $\gamma$




# ILCs

## In healthy

- Interspinous ligament and spinous process bone (healthy)
  - Higher % in entheses > blood
  - Produce IL-17 under IL-23





EST: enthesis  
PEB: perienthesal bone  
PB: peripheral blood  
MC: mononuclear cells



# ILC3 mice

## ► CIA mice




- ◆ CCR6+ ILC3s in joints with arthritis
  - ↑ Vs non-arthritic joints
  - expressed ↑ IL-17A and IL-22 mRNA Vs control mice



# ILC3

## AS - Gut

- ❖ Gut of AS patients
  - ❖ Overexpression of IL-7
  - ❖ ↑ ILC3
    - ❖ Produce IL-22
    - ❖ Produce IL-17





# ILC3

## AS-blood

### ILC3

- ◆ ↑ in AS Vs HC
- ↑ IL-17 & IL-22
- Express integrin  $\alpha 4\beta 7$



### Peripheral blood



# ILC3

## peripheral SpA - blood & synovial tissue


- per SpA (n=26), Knee arthritis
- Blood
  - ◆ ↑ % of ILC3 (NKp44+)
- Matched synovial tissue (ST), synovial fluid (SF), and peripheral blood (PB) samples
  - ◆ ↑ % of ILC3 in ST in SpA



# ILC3

## In peripheral SpA


- Synovial tissue
- ↑ Th17 signature transcripts (e.g *RORC*, *AHR*, and *IL23R*)
  - ◆ capable of inducing expression of *IL-22*
  - ◆ BUT not *IL-17A*, in response to in vitro restimulation.



# ILC3

## PsA - blood & synovial fluid



- ❖ HC (n=12), psoriasis (n=8), PsA (n=13)
  - ❖ Peripheral blood and synovial fluid
- ❖ ILCs
  - ❖ ↑ in PsA SF > PB
  - ❖ ↑ in PsA SF > RA SF



# ILC3

## PsA – synovial fluid

- ILCs in synovial fluid
  - IL-17 producing Vs RA
  - enriched for CCR6
    - Vs PsA PB
    - Vs RA SF



# summary


---

- ▶ ILC
  - ◆ ILC3 more important
    - ✿ Bowel ?
  - ◆ ↑ SpA/PsA
  - ◆ Target tissues>blood
    - ✿ migration
  - ◆ Produce IL-22
  - ◆ IL-17 in **some** cases

# PsA pathogenesis


## Rare subpopulations

- MAIT
- ILC
- Tgd



# Tgd Mice

- In Tcrd-H2BeGFP mice
- Tgd
  - ◆ abundant in uninflamed enthesal tissue
  - ◆ constituted the large majority of RORgt, IL-23R+ enthesis- resident lymphocytes
  - ◆ Produce IL-17
    - \* Under IL-23






# Tgd

## Accumulating in IL-23 overexpressing conditions

- In mice overexpressing IL-23

- ◆ Accumulation of Tgd cells
  - In entheses
  - In aortic root
  - In eye (ciliary body)



# Tgd

## In Healthy

- Spinal processes

- Entheses and bone

- Tgd cells

- 2 subsets

- V $\delta$ 2



- ✓ ↑ IL-23/17-associated transcripts  
(e.g IL-23R, RORC)

- V $\delta$ 1

- ✓ almost completely lacked detectable IL-23R transcript






- Produce IL-17

- ✓ Dependent OR NOT from IL-23



# Tgd AS/PsA - blood

- ❖ Peripheral blood
  - ❖ % of Tgd cells in AS & PsA
    - ✿ Contradicting results
  - ❖ ↑ % of IL-23R+ Tgd in AS and PsA
  - ❖ ↑ % of IL-17 Tgd in AS ≠ PsA
    - ✿ ↑ ↑ ↑ Express CCR6



## → ILC

- ◆ ILC3 more important
  - ✿ Bowel?
- ◆ ↑ SpA/PsA
- ◆ Target tissues>blood
  - ✿ migration
- ◆ Produce **IL-22**
- ◆ IL-17 in **some** cases

## → Tgd

- ◆ Important in entheses
- ◆ Produce IL-17
  - ✿ Irrespective or not of IL-23
  - ✿ AS ≠ PsA ?
  - ✿ Migration

## → MAIT

- ◆ Present and active in axial entheses
- ◆ Mani producers **of IL-17** (blood)
  - ✿ Under IL-7
- ◆ Migrate to joints?

# CyTOF

---

- ▶ Simultaneous -in depth analysis of cells subpopulations

1 Distinct innate and adaptive immunity phenotypic profile at the circulating single-cell level in Psoriatic Arthritis

3

4

5 George E. Fragoulis<sup>1,3</sup>, Eleni-Kyriaki Vetsika<sup>2</sup>, Maria Kyriakidi<sup>2</sup>, Kleio-Maria Verrou<sup>2</sup>,

6 George Kollias<sup>2</sup>, Maria G Tektonidou<sup>1</sup>, Iain B. McInnes<sup>3</sup>, Petros P. Sfikakis<sup>1,2</sup>



Clin Immun 2023 (In Press)

# Antibodies' panel (n=30)

Metal isotope	Target
89Y	CD45
141Pr	CD196/CCR6
143Nd	CD123
144Nd	CD19
145Nd	CD4
146Nd	CD8a
147Sm	CD11c
148Nd	CD16
149Sm	CD45RO
150Nd	CD45RA
151Eu	CD161
152Sm	CD194/CCR4
153Eu	CD25
154Sm	CD27
155Gd	CD57
156Gd	CD183/CXCR3
158Gd	CD185/CXCR5
160Gd	CD28

Metal isotope	Target
161Dy	CD38
163Dy	CD56/NCAM
164Dy	TCRgd
166Er	CD294
167Er	CD197/CCR7
168Er	CD14
170Er	CD3
171Yb	CD20
172Yb	CD66b
173Yb	HLA-DR
174Yb	IgD
176Yb	CD127

Intercalator	Role
103Rh	live/dead cell discrimination
191Ir	single nucleated
193Ir	cells/doublets discrimination

# 47 Immunocytic populations

A/A	Cells populations	A/A	Cells populations	A/A	Cells populations
1	<b>Granulocytes</b>	13	<b>Lymphocytes</b>	31	T regulatory (Tregs)
2	Neutrophils	14	<b>CD3<sup>+</sup> T cells</b>	32	Th1
3	Eosinophils	15	<b>CD8<sup>+</sup> cells</b>	33	Th2
4	Basophils	16	Immature	34	Th17
5	CD66b <sup>-</sup> Neutrophils	17	Central memory (CM)	35	<b>MAIT/NKT</b>
6	<b>Dendritic Cells (DC)</b>	18	Effector memory (EM)	36	$\gamma\delta$ T cells
7	Myeloid (mDC)	19	TE	37	<b>B cells</b>
8	Palsmatocytoid (pDC)	20	CD27 <sup>-</sup> CD28 <sup>-</sup>	38	Immature
9	<b>Monocytes</b>	21	Senescent(Tsen)	39	Memory
10	Classics	22	Senescent CD45RA <sup>+</sup> (Tsen-TEMRA)	40	IgD <sup>+</sup> memory
11	Intermediate	23	Activated	41	IgD <sup>-</sup> memory
12	Non-classic	24	CD127 <sup>+</sup> Activated	42	Age-associated B κύτταρα (ABCs)
		25	CD45RA <sup>+</sup> Activated	43	Plasmablasts
		26	<b>CD4<sup>+</sup> T cells</b>	44	<b>Natural Killer cells (NK)</b>
		27	Immature	45	Immature
		28	Central memory (CM)	46	Mature
		29	Effector memory (EM)	47	Innate lymphoid cells (ILCs)
		30	TE		

# Patients' characteristics

<b>Characteristics</b>	<b>PsA (n= 16)</b>	<b>RA (n= 21)</b>	<b>HC (n= 13)</b>
<b>Age (years)</b>			
Median (range)	49 (19-63)	55 (23-77)	51 (38-60)
<b>Gender</b>			
Female	12 (75%)	20 (95%)	9 (69%)
Male	4 (25%)	1 (5%)	4 (31%)
<b>Smoking</b>			
No	13 (81%)	14 (67%)	9 (69%)
Yes	3 (19%)	7 (33%)	4 (31%)
<b>Treatment</b>			
Naïve	5 (31%)	6 (29%)	-
csDMARDs-experienced	4 (25%)	11 (52%)	-
bDMARDs	7 (44%)	4 (19%)	-
<b>CRP (mg/L)</b>			
Mean (SEM)	8,31 (1,93)	20,54 (12,49)	-
<b>ESR (mm/h)</b>			
Mean (SEM)	25,56 (4,08)	35,33 (5,04)	-
<b>Disease activity score</b>	<b>DAPSA</b>	<b>DAS28</b>	
Mean (SEM)	16,86 (1,32)	4,91 (0,19)	-




	<b>RA (n= 21)</b>
<b>Seropositivity</b>	
Seronegative	9 (43%)
Seropositive	12 (57%)

# MAIT/iNKT, ILCs and $\gamma\delta$ T cells PsA and RA - peripheral blood


## PsA

- ◆  $\uparrow$  MAIT
- ◆  $\uparrow$  ILC
- ◆  $\downarrow$  Tgd
- ◆ Similarities with seronegative but not seropositive RA

HC = 13  
 PsA = 16  
 Seropositive RA = 12  
 Seronegative RA = 9




# MAIT/iNKT, ILCs and $\gamma\delta$ T cells & Migration PsA peripheral blood




## MAIT/iNKT

### Peripheral blood CCR6 (Increased in PsA)



# IL-23, IL-17 & migration

## The IL-17/IL-23 Axis: A Non-Linear Relationship<sup>1-6</sup>



# Conclusion, problems and questions

---

- ➔ SpA vs PsA
- ➔ Cell migration is important...
- ➔ Different tissues
  - ❖ Peripheral entheses Vs Axial entheses
    - \* Vs gut....Vs eye....

Thank you for your attention !! ☺